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Abstract
The majority of patients with pancreatic cancer present with disease that is unresectable due to local invasion. This article
reviews the evidence (or lack thereof) that chemoradiation therapy (CRT) helps these patients in four areas: survival, tumor
downstaging, palliation of obstructive symptoms, and pain control. We believe that CRT allows a small percentage of patients
with locally advanced disease to undergo potentially curative resection while providing effective palliative treatment.
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Introduction
By the time patients present with pancreatic cancer,
fewer than 10% have tumors that are amenable to
potentially curative resection. Approximately one-third
have distant metastatic disease and have a median
survival of less than 6 months. The rest (over half of
all patients with pancreatic cancer) have disease that is
considered unresectable due to local invasion of ad-
jacent structures. This heterogeneous group of patients
can be challenging to treat, as they generally have
problems related to their local tumor burden prior to
developing distant metastatic disease.
The term ‘unresectable’ is somewhat subjective, as
there are varying degrees of unresectability and varying
opinions on what constitutes unresectable disease.
We advocate neoadjuvant chemoradiation (CRT) for
patients with both potentially resectable and locally
advanced pancreatic cancer at our institution. We,
however, attempt to make a distinction between truly
unresectable disease and locally advanced disease.
Circumferential involvement or encasement of
the superior mesenteric artery (SMA) or celiac axis
represents truly unresectable disease. Although arterial
resection and reconstruction has been described for
this disease, the results are generally poor [1], due
not only to the morbidity of the procedure but also to
the perineural invasion often associated with arterial
involvement [2]. We do not necessarily classify non-
circumferential arterial involvement or abutment as
truly unresectable, as negative resection margins can
sometimes be achieved after neoadjuvant CRT.
Although thrombosis of the superior mesenteric vein
(SMV) or portal vein is associated with a prognosis
similar to patients with distant metastatic disease,
disease that involves the SMV and/or portal vein
without thrombosis can be resected and reconstructed
with good results [3–6]. In contrast to arterial in-
volvement, venous involvement does not necessarily
portend a poorer prognosis when compared to
tumors of similar size without venous involvement [3].
Similarly, adjacent organ invasion—although asso-
ciated with tumors of large size—is not technically
unresectable.
Finally, regional lymph node disease is often
discussed in the context of locally advanced disease,
despite its different biology. Regional lymph node
disease is often technically resectable: the question is
whether or not it is appropriate to do so. Although it
is clear that positive lymph nodes are one of the
most important predictors of recurrence following
resection [7], selected patients with positive lymph
nodes probably do better with resection than without
it. Regional lymph node disease should probably be
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considered separately from both locally advanced and
truly unresectable disease.
Studies of ‘locally advanced’ and ‘unresectable’
pancreatic cancer have used various definitions of
these terms, and comparison between studies can be
difficult. Despite this limitation, a number of studies
have established an important role for chemoradiation
therapy (CRT) in the management of locally advanced
or unresectable pancreatic cancer. This article reviews
the evidence (or lack thereof) that CRT helps in four
areas: survival, tumor downstaging, palliation of
obstructive symptoms, and pain control.
Survival
A series of randomized controlled trials spanning
the 1970s and 1980s provides strong evidence that the
combination of chemotherapy and radiation therapy
improves survival over either modality alone in patients
with locally unresectable disease. In the 1969 landmark
study by Moertel et al., survival was increased from
6 months with radiation alone to 10 months with 5FU
plus XRT [8]. A subsequent GI Tumor Study Group
(GITSG) study demonstrated the superiority of 5FU
plus XRT over XRT alone and even suggested a non-
significant survival advantage for using 60 Gy over
40 Gy [9]. Other randomized studies have corrobo-
rated the outcomes achieved with 5FU plus XRT but
have not managed to significantly improve upon
them by adding to or changing the chemotherapeutic
regimen [10,11]. Interestingly, no randomized con-
trolled study had been performed comparing CRT to
no CRT until a recent Japanese study demonstrated
a median survival of 13 months in patients receiv-
ing XRT plus continuous infusion 5FU, compared
to 6 months in patients receiving no treatment [12].
These studies have all focused primarily on recurrence
and survival as their endpoints, although no apparent
difference was seen with respect to local versus distant
disease progression.
Tumor downstaging
With the increased use of CRT for unresectable disease
came the observations that occasional patients had
dramatic responses to treatment that rendered them
resectable. Numerous institutions have now reported
their experiences with preoperative or ‘neoadjuvant’
CRT. Patient selection criteria and CRT regimens
have varied widely, and rates of resection following
neoadjuvant CRT have varied from 0% to 60%, with
most falling between 10% and 20% [13–27].
At our institution, we have now neoadjuvantly
treated almost 100 patients with ‘locally advanced’
disease, which excludes patients with only venous
abutment (potentially resectable) and excludes patients
with venous thrombosis (truly unresectable). Over the
years, our resectability rate has remained relatively
constant at approximately 18% [25,28]. Most of the
patients who were successfully resected with negative
margins had tumors with either venous involve-
ment alone or with very limited arterial involvement
(abutment). Interestingly, the median survival in this
group of patients is 20 months [25], which is similar
to patients at our institution who undergo surgery
first, followed by adjuvant CRT, and better than
patients treated with CRT alone.
To what extent this represents tumor downstaging
is difficult to definitively determine without exploring
all patients before and after CRT. In some cases, tumor
abutment on CT may represent peritumor pancreatitis
that resolves during CRT. Furthermore, a certain
proportion of these patients might have been resectable
if explored upfront, although the positive predictive
value of unresectability by CT is felt to be greater than
90% [29,30]. In general, radiographic responses to
CRT have been modest [25,31,32]. However, radio-
graphic responses do not correlate well with histologic
responses, and the replacement of tumor with fibrosis
that has typically been observed on histologic exami-
nation of resected surgical specimens may result in
little or no change in radiographic appearance. For
instance, approximately 10% of tumors that appear
locally advanced on restaging CT due to vascular
involvement can be resected because only sterile
fibrosis instead of viable tumor is found at exploration
[33]. However, when the complete tumor specimen
is examined pathologically after resection, we have
observed complete histologic responses in approxi-
mately 8% of patients with potentially resectable
tumors treated with neoadjuvant CRT, but in none
of the resected tumor specimens that were initially
classified as locally advanced [34]. It is our conclusion
from these data that tumor downstaging does occur
in a minority of patients with currently utilized
regimens.
Palliation of obstructive symptoms
Although it seems intuitive that local tumor control
should prevent or delay obstructive symptoms, very
few studies specifically address this role of CRT. In the
GITSG studies, for instance, an unspecified pro-
portion of patients had previously undergone palliative
surgical procedures. Most studies of palliative and
neoadjuvant CRT have not appreciated high rates
of isolated local progression, but local control is
notoriously difficult to evaluate. To our knowledge,
only one neoadjuvant CRT study has commented on
their low rate (less than 10%) of GI complications
in patients not undergoing resection [16]. In our
experience, median survival in patients with locally
advanced tumors who do not undergo resection
following neoadjuvant CRT is approximately 10
months. Gastrojejunostomy and/or biliary bypass had
been performed prior to CRT in 8% of patients and
following CRT in approximately 20% of patients at
the time of exploration to determine resectability.
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Only an additional 8% of patients required gastro-
jejunostomy for symptoms of gastric outlet obstruction.
Palliative surgical procedures were therefore performed
in almost 40% of unresectable patients but were pro-
phylactic in most. Prophylactic gastrojejunostomy has
been recommended to prevent an estimated risk of
gastric outlet obstruction of almost 20% [35], whereas
a more selective approach to surgical palliation has
been recommended by others [36]. These studies did
not specify what proportion of patients received
palliative CRT. We believe that we may be over-
treating by performing prophylactic surgical bypasses
in patients receiving CRT. The combination of endo-
scopic stenting and CRT may provide adequate
palliation and obviate the need for surgical bypasses in
the majority of these patients.
Pain control
For most patients with incurable pancreatic cancer,
pain control is or will become the most important
goal for improving the quality of their remaining life.
Increasing attention has been devoted to the incor-
poration of quality of life endpoints into clinical trials.
A ‘clinical benefit score’, assessing pain, weight gain,
and performance status, was developed by Burris et al.,
for the evaluation of chemotherapy for metastatic
pancreatic cancer [37]. When applied to patients
receiving CRT for locally advanced pancreatic cancer,
6 of 25 patients improved in at least one category
without deteriorating in another [38]. With respect
to pain control specifically, 5 of 25 patients had a
sustained decrease in analgesic consumption while
only 2 patients had an increase in analgesic consump-
tion. In the Japanese study mentioned above com-
paring XRT plus continuous infusion 5FU to no
treatment, 8 of 10 patients with pain prior to treat-
ment experienced pain relief lasting a median of
5 months [12].
Management of locally advanced
pancreatic cancer
CRT clearly improves survival, probably provides
pain control, and possibly helps to prevent obstructive
symptoms in patients with locally advanced pancreatic
cancer. CRT deserves to be considered the standard-
of-care for the palliative treatment of these patients. In
addition, we believe that there is compelling evidence
that a minority of patients with locally advanced
but not truly unresectable disease can be rendered
resectable by neoadjuvant CRT. Depending on the
institution and its available protocols, it may or may
not be necessary to distinguish between CRT with
neoadjuvant versus palliative intent, other than for
providing patients with realistic expectations. Many
radiation oncologists will treat palliatively with up to
60 Gy and utilize a more limited field. Our bias is
to treat with neoadjuvant intent, unless the patient has
truly unresectable disease, as defined above (arterial
encasement or venous thrombosis).
To summarize our treatment approach to patients
with locally advanced pancreatic cancer, all patients
first need a high-quality contrast-enhanced CT scan to
assess for distant metastatic disease and local resect-
ability. In jaundiced patients, ERCP is performed for
common bile duct brushings and for endoscopic stent
placement. In patients with truly unresectable disease,
metallic Wallstents may be more durable than the
typical plastic stents [39]. If endoscopic biliary drain-
age is unsuccessful, percutaneous biliary drainage
can usually be attained. If a cytologic diagnosis is not
obtained by ERCP, a tissue diagnosis must be obtained
by either image-guided percutaneous FNA or by EUS-
guided FNA prior to initiation of neoadjuvant or
palliative CRT. The presence of enlarged lymph nodes
on CT is relatively non-specific, and we attempt to
confirm regionally metastatic disease by EUS-guided
FNA. The role of staging laparoscopy prior to CRT
with neoadjuvant intent is unclear. One argument
against laparoscopy in this setting is that patients
with small-volume metastatic disease are probably
not harmed and may even be benefited by CRT.
However, for the purpose of studying the efficacy
of neoadjuvant CRT, staging laparoscopy is helpful
in excluding—to the extent possible—patients with
metastatic disease. Following CRT, patients undergo
restaging CT scan. The most important role of rest-
aging CT is the identification of distant metastatic
disease, which is consistently found in approximately
20% of patients following CRT. Our impression has
been that the appearance of arterial abutment or even
encasement on CT—typically considered indicative of
unresectability—may represent sterile fibrosis. EUS
with FNA has been employed in some patients to
obtain cytopathologic evidence that viable tumor cells
are present. Unless there is confirmation of arterial
Figure 1. An overview of our treatment approach to patients with
locally advanced pancreatic cancer.
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involvement or evidence of true unresectability by
CT, we give patients ‘the benefit of the doubt’ and offer
exploration for possible resection. An overview of our
current algorithm for locally advanced patients is
shown in Figure 1.
While the percentage of locally advanced patients
able to undergo potentially curative resection is
admittedly small with currently utilized CRT regi-
mens, this approach provides patients with a small but
realistic hope for longer survival without depriving
them of effective palliative treatment.
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